Published • loading... • Updated
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
Summary by biopharmadive.com
1 Articles
1 Articles
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
